• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Implants

Celanese to provide drug delivery platform for Glaukos glaucoma treatment

April 5, 2023 By Sean Whooley

Glaukos iDose

Celanese (NYSE:CE) announced today that it entered into an agreement with Glaukos (NYSE:GKOS) over drug delivery for glaucoma treatments. Dallas-based Celanese agreed to supply its VitalDose drug delivery platform for use as a component in Gluakos’ iDose TR. The iDose TR serves as a micro-invasive intraocular implant for lowering intraocular pressure. It treats patients with […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Implants, Optical/Ophthalmic Tagged With: Celanese, Glaukos

This implantable fuel cell generates electricity from glucose

March 29, 2023 By Sean Whooley

Prototype fuel cell for producing energy from glucose blood sugar (1)

A team of researchers developed an implantable fuel cell that uses excess glucose from tissue to generate electrical energy. By combining the fuel cell with artificial data cells, the team produced insulin with the touch of a button. This effectively lowered blood glucose levels like the natural process in the pancreas. Given that current treatments […]

Filed Under: Diabetes, Drug-Device Combinations, Implants, Research & Development Tagged With: ETH Zurich

This implantable drug delivery system is self-powered

March 24, 2023 By Sean Whooley

Shirley Ryan AbilityLab Northwestern self-powered drug delivery system LED light

Researchers at Shirley Ryan AbilityLab and Northwestern University developed technology that uses external light sources to trigger drug delivery. Yamin Zhang and Dr. Colin Franz of Shirley Ryan and John Rogers of Northwestern led the research team. They say their technology represents the first implantable drug delivery system triggered by external light sources. These light […]

Filed Under: Drug-Device Combinations, Featured, Implants, Pharmaceuticals, Research & Development, Technology Tagged With: Northwestern University

Vivani Medical wants to bring a subdermal drug delivery implant to the diabetes market

March 1, 2023 By Sean Whooley

Vivani NanoPortal diabetes implant

Where some have tried and failed, Vivani Medical believes its drug-delivering implants can go the distance. When Second Sight Medical and Nano Precision Medical merged last year, the rebranded company — Vivani Medical (Nasdaq:VANI)— had a goal: bring a six-month, subdermal drug delivery implant that treats conditions including type 2 diabetes to market. CEO Dr. […]

Filed Under: Diabetes, Drug-Device Combinations, Featured, Implants, Pharmaceuticals, Regulatory/Compliance, Technology Tagged With: Intarcia Therapeutics, Vivani Medical

Glaukos submits FDA New Drug Application for iDose TR drug-eluting implant

February 27, 2023 By Sean Whooley

Glaukos iDose

Glaukos (NYSE:GKOS) announced today that it submitted a New Drug Application (NDA) to the FDA for its iDose TR implant. Aliso Viejo, California-based Glaukos designed iDose TR as a micro-invasive intraocular implant. It continuously delivers therapeutic levels of a proprietary formulation of travoprost from within the eye over extended periods of time. Once all travoprost […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Optical/Ophthalmic, Regulatory/Compliance, Technology Tagged With: FDA, Glaukos

Evonik invests in Allay Therapeutics to reduce need for opioids

December 13, 2022 By Sean Whooley

Allay Therapeutics Evonik

Evonik announced today that it invested in Allay Therapeutics and its implant for treating pain after knee surgery. Inserted directly into the knee, the Allay implant may relieve pain for up to three weeks, according to a news release. Previous solutions worked for a maximum of three days, the company said. The technology helps promote […]

Filed Under: Business/Financial News, Drug-Device Combinations, Implants, Orthopedics Tagged With: Allay Therapeutics, Evonik

Cell Pouch System developer Sernova announces CEO transition

December 6, 2022 By Sean Whooley

Sernova Cell Pouch System Type 1 Diabetes

Sernova announced today that, as part of a planned leadership succession process, Dr. Philip Toleikis will transition out of the CEO role. Toleikis spent 13 years leading the Cell Pouch System developer as president and CEO. He remains an executive at the company as the planned transition moves him to chief technology officer (CTO). Additionally, […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Implants, Personnel Tagged With: Personnel, Personnel Moves, Sernova Inc

How Sernova seeks to treat insulin-dependent diabetes with its Cell Pouch System

November 21, 2022 By Sean Whooley

Sernova Cell Pouch System Type 1 Diabetes

When Dr. Philip Toleikis joined Sernova in 2009, the company’s technology appeared as more of a concept than anything else. But, he saw the potential for something groundbreaking: A cure for type 1 diabetes (T1D). “I just thought it was an incredible idea,” said Toleikis, who serves as Sernova’s president and CEO. “We spent a […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Implants Tagged With: Sernova Inc

Glaukos beats The Street in Q3

November 2, 2022 By Sean Whooley

Glaukos logo

Glaukos (NYSE:GKOS) shares hardly shifted on third-quarter results that came in ahead of the consensus forecast. The Aliso Viejo, California-based ophthalmic implant maker posted losses of $27.6 million in the quarter. That amounts to 58¢ per share on sales of $71.3 million for the three months ended Sept. 30, 2022. Glaukos registered a deep bottom-line […]

Filed Under: Business/Financial News, Drug-Device Combinations, Implants, MassDevice Earnings Roundup, Optical/Ophthalmic, Wall Street Beat Tagged With: Glaukos

BioCorRx completes enrollment in trial of naltrexone implant for treating opioid use disorder

October 13, 2022 By Sean Whooley

BioCorRx updated logo

BioCorRx (OTC:BICX) announced today that it enrolled the last subject in the Phase I clinical trial of its BICX104 implant. Anaheim, California-based BioCorRx designed BICX104 for the treatment of opioud use disorder (OUD). Its BioCorRx Pharmaceuticals company developed the implantable, biodegradable naltrexone pellet. “We are pleased to have reached this significant milestone,” said Brady Granier, […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Implants Tagged With: BioCorRx

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Interim pages omitted …
  • Page 24
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS